secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neumora Therapeutics, Inc. (NMRA)
CIK:        0001885522
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0000950170-25-069147
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neumora Q1 net loss $68M, secures $125M venture debt; navacaprant Ph3 data in 2026
--------------------------------------------------------------------------------

- Net loss $68.0M in Q1 2025, up from $53.7M in Q1 2024; R&D expense $52.2M (incl. $6.3M final Amgen costs).
- Cash, equivalents and marketable securities $249.4M as of March 31; plus $20M drawn from K2 HealthVentures extends cash runway into 2027.
- Entered $125M venture debt facility with K2 HealthVentures; $20M drawn, additional $20M available by Dec 31, 2025, $85M milestone-based.
- Navacaprant KOASTAL-3 topline data expected Q1 2026, KOASTAL-2 Q2 2026; NMRA-511 AD agitation data around end of 2025.
- M4 positive allosteric modulator (PAM) program expected to enter clinic in mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1885522/000095017025069147/0000950170-25-069147-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1885522/000095017025069147/nmra-20250512.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-069147

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer